Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment
Publication
, Other
Freedland, SJ; George, DJ; Moul, JW
Published in: Oncology Report
September 1, 2006
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2006
Issue
FALL
Start / End Page
51 / 52
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Freedland, S. J., George, D. J., & Moul, J. W. (2006). Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment. Oncology Report.
Freedland, S. J., D. J. George, and J. W. Moul. “Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment.” Oncology Report, September 1, 2006.
Freedland SJ, George DJ, Moul JW. Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment. Oncology Report. 2006. p. 51–2.
Freedland, S. J., et al. “Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment.” Oncology Report, no. FALL, 1 Sept. 2006, pp. 51–52.
Freedland SJ, George DJ, Moul JW. Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment. Oncology Report. 2006. p. 51–52.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2006
Issue
FALL
Start / End Page
51 / 52
Related Subject Headings
- Oncology & Carcinogenesis